Back to results
US 7,745,109 B2Granted
Regulation of cell growth by MUC1
AssigneeDana-Farber Cancer Insitute
InventorDonald W. Kufe
Life of this patent
Estimating the term…
Abstract
The invention features a method of identifying a compound that inhibits (a) the physical interaction (binding) between MUC1 and tumor progressors (e.g., β-catenin, c-Src, EGF-R, p120ctn, or PKCδ) and/or (b) phosphorylation of MUC1 by tumor progressors with kinase activity (e.g., c-Src, EGF-R, or PKCδ). The invention also includes a method of inhibiting an interaction between MUC1 and β-catenin and a method of inhibiting expression of MUC1 or a tumor progressor in a cell.
Claims23
A method of identifying a compound that inhibits binding of MUC1 to a tumor progressor, the method comprising:
- (a) providing a MUC1 test agent, wherein the MUC1 test agent comprises a phosphorylated YEKV site;
- (b) providing a tumor progressor test agent that has increased binding to the phosphorylated MUC1 test agent as compared to a MUC1 test agent that does not comprise a phosphorylated YEKV site;
- (c) contacting the phosphorylated MUC1 test agent with the tumor progressor test agent in the presence of a test compound;
- and
- (d) determining whether the test compound inhibits binding of the phosphorylated MUC1 test agent to the tumor progressor test agent.
2 more elements
Dependencies are inferred from the claim text.